Eli Lilly, Novo Nordisk Won Broader GLP-1 Sales Under $245 Deal Without Price Cuts
Updated
Updated · STAT · Jun 30
Eli Lilly, Novo Nordisk Won Broader GLP-1 Sales Under $245 Deal Without Price Cuts
3 articles · Updated · STAT · Jun 30
Summary
$245-a-month GLP-1 pricing promised by the Trump administration for Medicare and Medicaid was not guaranteed across all uses; Lilly and Novo could still gain broader coverage without lowering prices in some cases.
A previously undisclosed condition tied that price to private Medicare insurers agreeing to cover the drugs for all uses and charge patients a $50 copay.
Obesity GLP-1s were central to the bargain because Medicare had not previously covered them, making expanded coverage the main source of new volume for the drugmakers.
Novo Nordisk and Eli Lilly recently confirmed the hidden condition to STAT, undercutting the administration's public framing of the November deal as lower prices in exchange for higher sales.